Abstract
With a view to develop novel non-TZD anti-diabetic compounds, series of isoxazolidinediones were designed to target the PPAR-γ receptors. Docking studies were performed on co-crystallized protein structure of rosiglitazone with PPAR-γ receptor obtained from Protein Data Bank (2PRG). Interactions similar to that of rosiglitazone were observed for three molecules; 3a, 3b and 3c which were further synthesized and subjected to in vivo hypoglycemic, total cholesterol (CHL) and triglyceride (TG) evaluation. 14 days treatment revealed significant reduction in blood glucose levels but did not portray desirable results in terms of total CHL and TG lowering effect. The blood glucose reduction observed for 3a, 3b and 3c at 20 mg/kg/day was 53.96 %, 61.35%, 61.32% respectively as against 59.95% of the standard pioglitazone at 10mg/kg/day.
Keywords: 4-benzylidene-3, 5-isoxazolidinedione, docking, HFD- low STZ model, hypoglycemic activity , Knoevenagel condensation
Medicinal Chemistry
Title:Design, Synthesis and In-vivo Hypoglycemic Evaluation of Novel Non - TZD’S in a Type - 2 Diabetic Model
Volume: 9 Issue: 1
Author(s): Rupali Jadhav, Ranu Gupta-Rajoria, Tanushree Pal and Ramaa Chelakara Subramanian
Affiliation:
Keywords: 4-benzylidene-3, 5-isoxazolidinedione, docking, HFD- low STZ model, hypoglycemic activity , Knoevenagel condensation
Abstract: With a view to develop novel non-TZD anti-diabetic compounds, series of isoxazolidinediones were designed to target the PPAR-γ receptors. Docking studies were performed on co-crystallized protein structure of rosiglitazone with PPAR-γ receptor obtained from Protein Data Bank (2PRG). Interactions similar to that of rosiglitazone were observed for three molecules; 3a, 3b and 3c which were further synthesized and subjected to in vivo hypoglycemic, total cholesterol (CHL) and triglyceride (TG) evaluation. 14 days treatment revealed significant reduction in blood glucose levels but did not portray desirable results in terms of total CHL and TG lowering effect. The blood glucose reduction observed for 3a, 3b and 3c at 20 mg/kg/day was 53.96 %, 61.35%, 61.32% respectively as against 59.95% of the standard pioglitazone at 10mg/kg/day.
Export Options
About this article
Cite this article as:
Jadhav Rupali, Gupta-Rajoria Ranu, Pal Tanushree and Chelakara Subramanian Ramaa, Design, Synthesis and In-vivo Hypoglycemic Evaluation of Novel Non - TZD’S in a Type - 2 Diabetic Model, Medicinal Chemistry 2013; 9 (1) . https://dx.doi.org/10.2174/1573406411309010104
DOI https://dx.doi.org/10.2174/1573406411309010104 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Chemokine (C-X-C motif) Receptor 3 in Thyroid Autoimmunity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Cardioprotector Activity of an Esteroidal Saponin: A Scientific and Technological Prospection
Recent Patents on Biotechnology Retinoids: Impact on Adiposity, Lipids and Lipoprotein Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery An Overview of Computer-aided Drug Design Tools and Recent Applications in Designing of Anti-diabetic Agents
Current Drug Targets Use of Double-source Computed Tomography for Evaluation of the Relationship Between Smoking and Coronary Plaques
Current Medical Imaging Microcirculation in Hypertension: An Update on Clinical Significance and Therapy
Current Vascular Pharmacology Maternity Waiting Homes in Rural Districts in Africa; A Cornerstone of Safe Motherhood?
Current Women`s Health Reviews Patient Impressions of Possible Catastrophic Outcomes after Diabetic Foot Ulceration
Current Diabetes Reviews Vaginal Birth After Cesarean: How to Counsel Patients Using the Evidence
Current Women`s Health Reviews Secretory Expression of Human Protein in the Yeast Pichia pastoris by Controlled Fermentor Culture
Recent Patents on Biotechnology Can Life Before Birth Affect Health Ever After?
Current Women`s Health Reviews SARS: Understanding the Virus and Development of Rational Therapy
Current Molecular Medicine Cerebrovascular Damage as a Cause for Alzheimers Disease
Current Neurovascular Research Phytotherapy and NAFLD - from Goals and Challenges to Clinical Practice
Reviews on Recent Clinical Trials Recent Patents on Immunoregulatory DNA Vaccines for Autoimmune Diseases and Allograft Rejection
Recent Patents on DNA & Gene Sequences Amorphous or Crystalline? A Comparison of Particle Engineering Methods and Selection
Current Pharmaceutical Design Antivirals Used for Influenza Chemoprophylaxis
Current Medicinal Chemistry Hepatocellular Carcinoma: Beyond the Boundaries of Age
Anti-Cancer Agents in Medicinal Chemistry Management of Type 2 Diabetes: More Evidence is Required to Address the Clinical and Contextual Facets
Current Diabetes Reviews Advanced Glycation End Products and Insulin Resistance
Current Pharmaceutical Design